Review finds mindfulness meditation offers only small mental health benefits

Mindfulness meditation showed only small gains in a systematic review of 117 trials, and once the statistics were corrected the only durable effect was that people said they felt more mindful. The analysis found small effects on depression, stress and emotion regulation, but no clear benefits for anxiety or behavior, a sharp reminder that the practice is not the broad mental health fix popular coverage often promises.

That reality check lands in a field where use has surged. The National Center for Complementary and Integrative Health says U.S. adult meditation use rose from 7.5% in 2002 to 17.3% in 2022, making meditation the most popular complementary health approach measured in the National Health Interview Survey, ahead of yoga, chiropractic care and massage therapy.

NCCIH also separates casual practice from the structured programs that dominate clinical research. Mindfulness-based stress reduction includes discussion sessions and other strategies, while mindfulness-based cognitive therapy combines mindfulness with cognitive behavioral therapy principles. Safety remains a live question: a 2020 review of 83 studies involving 6,703 participants found 55 studies reported negative experiences related to meditation, and about 8% of participants had a negative effect.

The new review sits beside older evidence that was already more restrained than many wellness claims. A 2014 JAMA Internal Medicine meta-analysis by Madhav Goyal, Sonal Singh, Erica M. Sibinga and colleagues screened 18,753 citations, reviewed 47 trials with 3,515 participants, and found moderate evidence of small-to-moderate reductions in anxiety and depression, low evidence for stress, distress and mental-health-related quality of life, and no evidence that meditation programs outperformed active treatments such as drugs, exercise or other behavioral therapies.

There is still a narrower case for targeted use. In May 2025, a trial from the University of Exeter, the University of Surrey and Sussex Partnership NHS Foundation Trust reported that mindfulness-based cognitive therapy significantly improved depression symptoms in people with difficult-to-treat depression, involved more than 200 patients, and was described as cost-effective at less than £100 per person. That matters in the NHS Talking Therapies programme, which treats around 670,000 people a year and still leaves almost half of those treated for depression with some degree of depression at the end of care.

The clean read is the one the 117-trial review forces: mindfulness can still help, especially in structured programs and specific clinical settings, but the strongest evidence no longer supports selling it as a cure-all. If you try it, look for MBSR or MBCT, expect modest gains, and judge it by whether it changes stress or attention, not by promises to fix every mood problem at once.